RxDoctor Payments DataLook up a doctor →

John Poulos, MD

Gastroenterology · Fayetteville, NCNPI 1578596896

Payments from drug & device makers

$2,136,703in general payments, 2019–2025

Across 892 payments — averaging $2395.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$679K
  • Genentech, Inc.$426K
  • Madrigal Pharmaceuticals$256K
  • Intercept Pharmaceuticals, Inc.$191K
  • Intercept Pharma Europe Ltd.$145K
  • Gilead$126K
  • plus $313K from 36 others
$1,217in research payments, 2019–2025

Across 2 payments — averaging $608.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$1K

What the payments were for

  • Consulting fees$2,2491%
  • Speaking & faculty fees$373,96992%
  • Travel & lodging$21,0015%
  • Food & beverage$9,6142%
  • Education$1690%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,136,703 in reported general payments places this provider in the 95th percentile of 610 gastroenterology providers in North Carolina.

See all gastroenterology providers in North Carolina

Medicare billing

Part B allowed, 2024
$327,363
Medicare patients
596
Services billed
7,633

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira PenAdalimumab18$234,924
OcalivaObeticholic Acid11$105,070
LinzessLinaclotide116$98,265
CreonLipase/Protease/Amylase20$62,240
XifaxanRifaximin15$26,500
VoqueznaVonoprazan Fumarate16$10,141
MovantikNaloxegol Oxalate11$4,694
Omeprazole188$2,872
Mesalamine22$2,158
Rabeprazole Sodium92$1,960
Ursodiol16$1,632
Lubiprostone11$1,570
Budesonide DrBudesonide13$1,168
Cholestyramine LightCholestyramine12$787
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine30$542

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$679,286$160,504136 claims
Intercept Pharmaceuticals, Inc.Ocaliva$190,983$105,07011 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$256$26,50015 claims
Phathom Pharmaceuticals, Inc.Voquezna$105$10,14116 claims
Redhill Biopharma Inc.Movantik$25$4,69411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 610 gastroenterology providers in North Carolina.

Other gastroenterology in Fayetteville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →